WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Oula Yousef Nfelah*, Tagrid Kaddar and Firas Hussein

ABSTRACT

Determination of prognostic factors in Hodgkin’s Lymphoma patients plays an important role in reducing intensive chemotherapy, decreasing economic costs, and improving the outcome of the patients. We conducted this study to determine the prognostic value of [lymphocyte/monocyte ratio (LMR)] in Classical Hodgkin’s Lymphoma patients (cHL) [trying to establish a relationship between it, overall survival (OS) & progression free survival (PFS)]. Also, we wanted to study the relationship between LMR and other variables such as age, sex, histological type, white blood cells, absolute lymphocyte count, absolute monocyte count, hemoglobin, serum albumin, Ann Arbor Staging, B-Syptoms, early or advanced stages, bulky mediastinal mass, type of primary treatment if chemotherapy alone or radiochemotherapy and the effect of these variables on OS and PFS. A retrospective study included 242 patients with cHL admitted to the center of radiochemotherapy in Tishreen University Hospital in Lattakia from January 2011 to December 2015. We monitored the patients until 1st September 2020. An LMR at diagnosis of 2.9 or more was the best cut-off value for survival. In univariate analysis, patients with LMR < 2.9 had inferior OS and PFS. LMR had an important prognostic value in patients with limited or advanced stages. In multivariate analysis, LMR was an independent prognostic factor for survival and to predict clinical outcomes in patients with classical Hodgkin’s lymphoma. In conclusion, LMR provides a simple model to assess clinical outcomes in cHL.